Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regadenoson in MDCT vs SPECT for CAD
NCT01334918Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regadenoson in coronary artery disease (CAD), sponsored by Astellas Pharma. Started Apr 2011; status: completed.
02
Drugs
regadenoson
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01334918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01334918.